Insmed to Host Investor and Analyst Event on May 8, 2023

Rhea-AI Summary

Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company dedicated to treating serious rare diseases, will host an investor and analyst event titled "The Future of Rare at Insmed" on May 8, 2023, from 8:00 a.m. to 12:00 p.m. ET in New York. The event will focus on Insmed's early-stage research programs and feature presentations from management and research leaders discussing their innovative platforms. The company aims to develop at least six new investigational new drug applications by 2025. A live webcast will be available on their website, with a replay accessible 30 minutes after the event's conclusion. Insmed's mission includes advancing therapies targeting unaddressed medical needs in rare pulmonary disorders and other serious conditions.

— The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More—

BRIDGEWATER, N.J., April 24, 2023 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will host an investor and analyst event on Monday, May 8, 2023. The event, titled "The Future of Rare at Insmed: Functional Genes, AI-Enhanced Proteins, Glowing Algae, and More," will take place from 8:00 a.m. to 12:00 p.m. ET in New York and will be simultaneously webcast. 

The agenda will include a deep dive into Insmed's early-stage research programs. Members of the management team will be joined by Insmed's Deimmunized by Design, gene therapy, and protein manufacturing team leaders to unveil the platforms and capabilities that the company believes will generate at least six new investigational new drug applications by 2025.

A live webcast will be available on the company's website at www.insmed.com. A replay of the event will be accessible approximately 30 minutes after its completion. A copy of the presentation materials and webcast will be archived for 90 days under the Investor Relations section of the company's website at www.insmed.com.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is also progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is headquartered in Bridgewater, New Jersey, with a footprint across Europe and in Japan. For more information, visit www.insmed.com.

Contact:

Investors:

Bryan Dunn
Executive Director, Investor Relations
Insmed
(646) 812-4030
bryan.dunn@insmed.com

Eleanor Barisser
Associate Director, Investor Relations
Insmed
(718) 594-5332
eleanor.barisser@insmed.com

Media:

Mandy Fahey
Executive Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com

 

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-to-host-investor-and-analyst-event-on-may-8-2023-301805111.html

SOURCE Insmed Incorporated

FAQ

What is the date and time of Insmed's investor event?

Insmed's investor and analyst event will take place on May 8, 2023, from 8:00 a.m. to 12:00 p.m. ET.

Where will the Insmed event be held?

The event will be held in New York.

What is the focus of the Insmed investor event?

The event will focus on Insmed's early-stage research programs and their plans for new investigational new drug applications.

How many investigational new drug applications does Insmed plan to develop by 2025?

Insmed aims to generate at least six new investigational new drug applications by 2025.

Will there be a webcast available for the Insmed event?

Yes, a live webcast will be available on Insmed's website, along with a replay accessible 30 minutes after the event.